Curium Pharma agreed to acquire Lantheus Holdings in a definitive deal valued at up to $8 billion, strengthening both firms’ theranostics and radiodiagnostics footprints. Curium will pay $114.50 per Lantheus share, including $102.50 at closing and contingent value rights tied to product sales for up to an additional $12 per share. The combined strategy is centered on pairing Curium’s global theranostics manufacturing platform with Lantheus’ leading U.S. radiodiagnostics franchise, a pairing intended to expand geographic reach and portfolio execution capacity. The deal reflects continued consolidation in radiopharma as companies push to scale production and distribution for targeted imaging and therapy. The transaction is expected to close under standard conditions, subject to approvals and customary deal terms, as firms compete to secure supply chains and clinical momentum in PSMA- and other target-driven radioligand ecosystems.